Physician profile
Sassan Farjami
NPI 1134154594
$47,830.58
in general payments reported to CMS, 2019-2025
70 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,893 · 2020: $9,730 · 2021: $8,474 · 2022: $3,887 · 2023: $4,258 · 2024: $2,185 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278 · Consulting Fee: $7,147 · Travel and Lodging: $968 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,278.43 |
| Consulting Fee | $7,147.00 |
| Travel and Lodging | $967.69 |
| Education | $452.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13,853.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,608.26 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Geron Corporation | $3,242.73 | 2025 | Imetelstat |
| Pfizer INC. | $2,847.20 | 2019-2025 | |
| Incyte Corporation | $2,516.24 | 2020-2025 | Jakafi, Monjuvi, Monjuvi |
| Cti Biopharma Corp. | $2,500.00 | 2022 | |
| Karyopharm Therapeutics INC. | $2,347.47 | 2021-2025 | Xpovio |
| Seagen INC. | $2,137.18 | 2019-2025 | Padcev |
| Eisai INC. | $1,793.15 | 2019-2025 | |
| Janssen Biotech, INC. | $1,663.56 | 2019-2025 | Rybrevant, Carvykti, Tecvayli |
| Athenex Pharmaceutical Division, LLC | $1,600.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,522.81 | 2019-2025 | |
| Exelixis INC. | $996.97 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $525.73 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $502.62 | 2021-2025 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $474.16 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $400.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $397.18 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $394.18 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Array Biopharma INC | $340.67 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Alexion Pharmaceuticals, INC. | $328.86 | 2022-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $315.33 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $278.66 | 2024-2025 | Enhertu, Datroway |
| Sobi, INC | $229.30 | 2024-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Lilly USA, LLC | $184.53 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $162.23 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Gilead Sciences, INC. | $158.82 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $141.64 | 2024-2025 | |
| Celgene Corporation | $130.49 | 2019-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $129.56 | 2019-2025 | |
| Pharmaessentia USA Corporation | $115.35 | 2024-2025 | Besremi |
| Genentech USA, INC. | $104.18 | 2019-2025 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $100.94 | 2025 | Libtayo, Lynozyfic |
| Comsort, INC | $100.00 | 2019 | |
| Coherus Oncology, INC. | $89.22 | 2020-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.37 | 2019-2025 | Gilotrif |
| Emd Serono, INC. | $84.34 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $76.49 | 2024-2025 | |
| Puma Biotechnology, INC. | $71.85 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $68.55 | 2019-2020 | |
| Beone Medicines USA, INC. | $68.48 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $66.05 | 2024-2025 | |
| Foundation Medicine, INC. | $63.03 | 2019 | |
| Beigene USA, INC. | $62.33 | 2024-2025 | Brukinsa |
| Springworks Therapeutics, INC. | $59.13 | 2025 | Ogsiveo |
| Genmab U.S., INC. | $58.55 | 2024-2025 | Epkinly |
| Sumitomo Pharma America, INC. | $57.44 | 2024-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $55.12 | 2025 | Clonoseq |
| Stemline Therapeutics INC. | $53.86 | 2019-2025 | Orserdu |
| Progenics Pharmaceuticals, INC. | $50.74 | 2025 | |
| Caris Mpi, INC. | $29.79 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $28.65 | 2024 | |
| Mirati Therapeutics, INC. | $28.65 | 2024 | Krazati |
| Radius Health, INC. | $28.07 | 2025 | Tymlos |
| Blueprint Medicines Corporation | $26.00 | 2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $25.60 | 2019 | |
| Kite Pharma, INC. | $24.23 | 2021 | |
| Kyowa Kirin, INC. | $23.50 | 2025 | |
| Spectrum Pharmaceuticals INC. | $22.18 | 2024 | Rolvedon |
| Adc Therapeutics America, INC. | $21.99 | 2025 | |
| Secura Bio, INC. | $21.02 | 2025 | Copiktra |
| Recordati_rare_diseases_inc. | $20.94 | 2025 | Enjaymo |
| Dendreon Pharmaceuticals LLC | $20.52 | 2020 | |
| Boston Scientific Corporation | $19.85 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Rigel Pharmaceuticals, INC. | $19.27 | 2024 | Tavalisse, Rezlidhia |
| Chiesi USA, INC. | $17.23 | 2025 | Ferriprox |
| Shorla Oncology INC. | $16.73 | 2025 | |
| Pharmacosmos Therapeutics INC. | $16.31 | 2025 | Monoferric |
| Janssen Pharmaceuticals, INC | $5.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sassan Farjami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.